Dupilumab (Dupixent) for severe eczema in infants

IRB
CHLA-17-00542
A Phase 2/3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged ≥6 Months to <6 Years with Severe Atopic Dermatitis

To find out safety and effectiveness of dupilumab (Dupixent) in infants with severe eczema.

Study Details
Clinical Trials Government Identifier
NCT03346434
Keywords
dupilumab atopic dermatitis, skin, dupixent
Eligibility
Aged ≥6 months to <6 years with Severe Atopic Dermatitis (eczema) that is not responsive to steroids
Does this study also recruit healthy volunteers?
No
Enrollment Status
Closed
Coordinator Contact
Sydney Brown
Contact Email
sybrown@chla.usc.edu
Contact Email
pyong@chla.usc.edu